Osteosarcoma in dogs and children genetically similarJuly 26, 2019The veterinary community might soon see advancements in the treatment of canine osteosarcoma (OS).
SPONSORED CONTENTYour Parasite Protection Recommendation, SimplifiedManaging parasite prevention doesn’t have to be complicated. Discover a single solution that protects against multiple threats. + Learn More
Cancer treatment company plans for public offeringJuly 25, 2019PetCure Oncology has engaged Boustead Securities for a Regulation D 506(c) offering.
VetStem receives immunotherapy license from human health firmJuly 15, 2019Biopharmaceutical animal health company VetStem has partnered with Calidi Biotherapeutics, a clinical‐stage biotechnology company specializing in the stem cell-based delivery of oncolytic virus-based immunotherapies for cancer.
Is chemotherapy a viable treatment for lymphoma in horses?June 25, 2019 Lymphoma, which is cancer of the lymphatic system, is a rare medical condition of horses. However, it also is the most common malignant neoplastic condition of the horse system. Horses of any age can be affected, although it more commonly appears earlier in life (from four to 10 years of age). Lymphoma has several manifestations: multicentric, in the gastrointestinal tract, in the skin, and even in discrete settings. This disease can be difficult to recognize initially, and is typically diagnosed after it has progressed, with clinical signs relative to the affected organ or tissue. Routine hematological analysis is often not helpful, as complete blood counts and serum chemistry tests are usually normal. When hematological abnormalities do occur, they typically show as anemia, increased serum protein, and/or fibrinogen. Conversely, low serum protein levels may be seen, as well. A definitive diagnosis is made by identifying neoplastic lymphocytes, usually obtained by analysis of body fluid effusions (e.g. pleural or abdominal fluid, or by fine needle aspiration of affected tissue[s]). Depending on the form of lymphoma and how late in the disease process the horse is presented, the prognosis is usually poor. There are several treatment options, including surgical removal of isolated, …
Ohio State opens expanded veterinary oncology suiteMay 29, 2019Ohio State University's Veterinary Medical Center has opened the Blue Buffalo Foundation Integrated Oncology Suite, allowing practitioners to comprehensively and holistically treat pets with cancer. Blue Buffalo granted the school $650,000 to renovate the suite. "Blue Buffalo was founded on a mission to help cure a disease causing 50 percent of health-related pet deaths," says the company's vice president, David Petrie. "In supporting the renovation of the integrated oncology space, we are able to support veterinary medicine so dogs and cats facing cancer can receive a cohesive team approach, resulting in better health outcomes." The suite's team comprises veterinarians with specialties in medical, surgical, and radiation oncology. Clinical trials also are a big part of the integrated oncology service and are managed by the Blue Buffalo Veterinary Clinical Trials Office. The company's funding will help support animals enrolled in a study. "Our partnership with Blue Buffalo has made it possible to provide studies that test new diagnostics and treatments across a wide spectrum of pet health, including cancer, renal failure, heart disease, and arthritis," says Cheryl London, DVM, PhD, clinical trials office director and professor of veterinary biosciences. "Clinical trials in veterinary medicine are critical for identifying new approaches to …
TGen, Ethos develop diagnosis test for canine lymphomaMay 24, 2019A new test may assist veterinarians in more accurately diagnosing canine lymphoma. Developed by Ethos Veterinary Health, Ethos Discovery, and the Translational Genomics Research Institute (TGen), the test is based on the results of a study that analyzed 180 dogs with cancer. The teams used their test, ePARR, to confirm first whether the dogs in the study had lymphoma and then determined what type they had. Results indicate the test was more than 90 percent accurate among a range of lymphoma sample types. "An ongoing need exists for robust validation of molecular diagnostics in veterinary medicine. This study is an example of exhaustive validation of one such molecular test," says Will Hendricks, PhD, assistant professor in TGen's Integrated Cancer Genomics Division and one of the study's senior coauthors. "Overall, ePARR is more than 90 percent accurate across sample types and diagnostic settings." The researchers say not only could molecular-level investigations into dog DNA improve the health of dogs with cancer, but it could help understand cancer in humans, too.
Petco Foundation, Blue Buffalo invest $15 million in pet cancer researchMay 14, 2019Petco Foundation and Blue Buffalo announced they have invested $15 million in pet cancer research and treatment since starting the Pet Cancer Awareness campaign in 2010. Not only that, their goal is to raise an additional $2.6 million this year to support innovative programs at veterinary oncology universities in the U.S., and to continue to help owners afford the cost of cancer treatments for their pets. "Blue Buffalo has been committed to finding a cure for pet cancer since our inception," says the company's vice president, David Petrie. "We are excited about collaborative efforts, together with Petco and the Petco Foundation, to raise funds for research, increase awareness of cancer warning signs, and help pet parents with the cost of pet cancer treatment." Funds raised in the campaign will go toward new investments such as Oklahoma State University's Center of Veterinary Health Sciences, which is focused on ultrasound cancer treatment. The therapy would provide a noninvasive, nontoxic alternative to surgery, radiation, and chemotherapy. Further, additional investments to 10 university veterinary oncology centers will help assist owners cover the cost of cancer treatments for their pets. Petco Foundation will also be launching a fund to help animal welfare organizations offset cancer …
ASU begins clinical study for cancer-preventing vaccineMay 10, 2019An Arizona State University (ASU) professor has begun a five-year clinical study examining the effectiveness of a cancer-preventing vaccine for dogs. Stephen Johnston, PhD, a scientist, professor at the School of Life Sciences, and director of the Biodesign Center for Innovations in Medicine, developed the vaccine over a span of 12 years. He says his goal is to change the way veterinarians treat cancer by preventing it before it can start. Over the course of the five-year study, 800 dogs will either be given the vaccine or a placebo and will be monitored. The University of Wisconsin (UW) School of Veterinary Medicine, Colorado State University (CSU) and University of California (UC), Davis are also participating in the trial. "We're testing a totally novel way of creating an anticancer immune response," says David Vail, DVM, DACVIM (oncology), professor and board-certified oncologist at the UW School of Veterinary Medicine. "The holy grail would be to prevent cancer as opposed to waiting for it to start and then treating it." The vaccine is designed to target common canine cancers, including lymphoma, osteosarcoma, hemangiosarcoma, and mastocytomas. At the beginning, two sets of vaccines will be given every two weeks and then annually. The …
Blue Buffalo and Petco Foundation award cancer research grant to Morris Animal FoundationMay 1, 2019Blue Buffalo and Petco Foundation have joined forces to award a $250,000-grant to Morris Animal Foundation to fund its feline cancer studies. "Blue Buffalo is thrilled to partner once again with Petco Foundation to support Morris Animal Foundation in its fight against cancer, a terrible disease causing 50 percent of health-related pet deaths," says company vice-president, David Petrie. "Research is expensive, and we are proud to help fund studies that will lead to better health outcomes for dogs and cats." Cancer is the second leading cause of death in cats. In the U.S., more than 12 million pets are diagnosed with the disease every year. Since 1962, Morris Animal Foundation has funded more than 300 cancer studies and invested approximately $40 million. "We are deeply grateful for this meaningful gift, which will help us continue to advance cancer care," says Morris Animal Foundation president and chief executive officer, Tiffany Grunert. "It is through support like this that we're able to fund the best, most impactful studies, forging a path to a world where all cancers are treatable and more cures possible." Funding for Morris Animal Foundation has led to multiple breakthroughs and advancements in cancer care animals everywhere. This …
Omega-3 supplements and hypothyroidism linked to decline of T-zone lymphomaApril 4, 2019A study at Colorado State University (CSU) has found dogs who receive omega-3 fatty acid supplements or have hypothyroidism may be less likely to develop T-zone lymphoma (TZL). The findings come from Morris Animal Foundation-funded researchers who looked at associations of the environment and health history of TZL among golden retrievers. T-zone lymphoma is a type of cancer, which progresses slowly and is usually found in older dogs. It is predominantly found in golden retrievers; however, Anne Avery, DVM, PhD, associate professor in the department of microbiology, immunology, and pathology at CSU, believes the underlying causes of the tumor are shared across breeds. "Although controlled prospective studies would be necessary to firmly establish protection by omega-3 fatty acids, our observations raise the possibility of a simple intervention, which may help reduce the frequency of this disease," Dr. Avery says. "We were also a little surprised to discover defective genes leading to another, seemingly unrelated disorder— hypothyroidism—are more common in dogs who do not develop T-zone lymphoma." More than 350 golden retrievers were used in the study, which looked at health history questionnaires and blood or biological samples. The dogs were divided into two groups. One of the groups …
